Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United Kingdom, Canada, Japan, Europe, China
Iran, the second-largest country in the Middle East, has a growing demand for dermatological drugs. The market is driven by several factors such as the increasing prevalence of skin diseases, rising awareness about skincare, and the availability of advanced treatment options.
Customer preferences: Iranian consumers have a strong preference for natural and herbal products, which are perceived to be safer and have fewer side effects. However, there is also a growing demand for advanced dermatological drugs that offer more effective treatment options. Consumers are willing to pay a premium for high-quality products that can improve their skin health.
Trends in the market: The Iranian dermatological drugs market is expected to experience significant growth in the coming years. This growth is driven by an increase in the prevalence of skin diseases such as acne, psoriasis, and eczema. According to a report by the World Health Organization (WHO), the prevalence of skin diseases in Iran is around 13%, which is higher than the global average. This has led to an increase in demand for dermatological drugs.
Local special circumstances: Iran has a large population of young people who are increasingly concerned about their appearance and skin health. This has led to a growing demand for skincare products and dermatological drugs. In addition, the Iranian government has taken steps to promote the production of local pharmaceuticals, which has led to the emergence of several domestic players in the market.
Underlying macroeconomic factors: The Iranian economy has been facing several challenges in recent years, including sanctions and a decline in oil prices. However, the pharmaceutical industry has been relatively resilient, with the government investing heavily in the sector. The Iranian government has also implemented policies to improve access to healthcare services, which has led to an increase in demand for dermatological drugs. Additionally, the growing middle class in Iran has more disposable income to spend on healthcare products, including dermatological drugs. In conclusion, the Iranian dermatological drugs market is expected to experience significant growth in the coming years, driven by an increase in the prevalence of skin diseases, rising awareness about skincare, and the availability of advanced treatment options. The market is characterized by a strong preference for natural and herbal products, as well as a growing demand for high-quality dermatological drugs. The Iranian government's policies to improve access to healthcare services and promote the production of local pharmaceuticals are also contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)